Rationale: Transforming growth factor-beta (TGFβ) is tightly regulated at multiple levels, with regulation at 30 the receptor level now recognized as a key determinant of the cellular response to this pleiotropic cytokine. 31
Introduction

55
Coronary artery bypass grafting (CABG) is a mainstay in the treatment of coronary artery disease 56 (CAD), with over 400,000 CABG surgeries performed per annum in the United States alone [1] . However, 57 fewer than 60% of saphenous vein grafts (SVG) remain patent in the long-term (>10yrs) due to the formation 58 of a hyperplastic, occlusive neointima within the grafted vessel [2] . Smooth muscle cell (SMC) hyperplasia 59 and matrix biosynthesis are key drivers of vein graft intimal hyperplasia (IH), which is a fertile substrate for 60 the accelerated development of rupture-prone atherosclerotic plaques [3, 4] . SMC hyperplasia has therefore 61 been identified as an important target for therapeutic interventions aimed at improving outcomes after CABG 62 surgery [5] . 63
The pleiotropic cytokine transforming growth factor-beta (TGFβ1) is highly expressed in re-stenotic 64 vessels from CAD patients and is acutely upregulated following vein graft implantation in animal models of 65 vein graft disease, inducing constrictive and fibrotic vascular remodelling [6] [7] [8] . However, to date most studies 66 investigating the role of TGFβ in IH have used global approaches to target TGFβ, or have focused on the 67 canonical TGFβ type I receptor (also termed activin receptor-like kinase 5/ALK5), Smad2/3-mediated 68 pathway. TGFβ elicits a diverse range of cellular responses by activating different signaling pathways, and in 69 certain cell types can also signal via a distinct type I receptor, activin receptor-like kinase 1(ALK1), activating 70 a separate set of receptor-regulated (R)-Smad proteins (Smad1/5) that can antagonize ALK5 signaling [9] . 71
Interestingly, a recent study showed that vascular injury-induced upregulation of KLF6 (Kruppel-like growth 72 factor 6) in endothelial cells (ECs) was associated with increased expression of ALK1 in neighboring SMC 73 [10] . Moreover, mutations in exon 10 of the ACVRL1 gene (encodes ALK1) are associated with pulmonary 74 arterial hypertension, a fatal condition that is characterized by the development of IH within the small 75 pulmonary arteries [11] . Although this points to a potentially relevant role for ALK1 in SMC during 76 neointima formation, studies have so far failed to show whether TGFβ is able to signal via ALK1 in human 77
SMCs. The role of SMC ALK1 during the development of vein graft IH has also yet to be defined. Here we 78
show that whilst TGFβ signaling via ALK5 is associated with SMC contractility and fibrosis, activation of 79 ALK1 promotes neointima formation by inducing a distinct transcriptional network that drives SMC 80 migration, identifying this pathway as a potential therapeutic target in the setting of vein graft failure (VGF). 81
Results 83 84
TGFβ1 signals through ALK1 in saphenous vein SMCs 85
The expression pattern and abundance of TGFβ receptors varies substantially between cell types, 86 influencing the cellular response to TGFβ stimulation. We therefore set out to characterize the expression and 87 activation of TGFβ receptors in SMC outgrowth cultures (HSVSMC) from saphenous vein segments obtained 88 from patients undergoing CABG surgery. ALK1, ALK5, TβR2 (TGFβ type II receptor) and the accessory 89
TGFβ receptors endoglin (ENG) and betaglycan (TβR3) were widely expressed in HSVSMC at the RNA level 90 (n=7-12 patients, Fig.1A ). Affinity labeling and crosslinking studies using I 125 TGFβ indicated binding of 91 TGFβ to all these receptors in HSVSMC, with particularly strong binding to ALK5, ENG and TβRIII/ TβR3 92 ( Fig.1B ). Activation of ALK receptors induces R-Smad phosphorylation, initiating a cascade of receptor-93 specific downstream events that culminate in the translocation of phosphorylated R-Smad proteins to the 94 nucleus [12] . Immunoblotting revealed that treatment with even low doses of TGFβ (0.1ng/mL) could induce 95 a rapid increase in pSmad1/5 as well as pSmad2 (Fig.1C, upper [pSmad2] and lower [pSmad1/5] panels), 96 while immunocytochemistry confirmed the nuclear localization of both pSmad1/5 and pSmad2/3 signaling 97 complexes following stimulation of HSVSMC with TGFβ ( Fig.1D ). QRT-PCR evaluation of the prototypical 98 ALK1 and ALK5 gene targets inhibitor of differentiation-1(ID1; ALK1/pSmad1/5 target) and plasminogen 99 activator inhibitor-1(PAI1/SERPINE1; ALK5/pSmad2/3 target) was consistent with activation of both 100 pathways by TGFβ at the transcriptional level ( Fig.1E and 1F ). Importantly, pharmacological inhibition 101 (using the ALK1 kinase inhibitor KO2288/KO, or the ALK5 kinase inhibitor SB525334/SB; Supplemental 102 HSVSMC reduced the expression of pSmad1/5 and pSmad2, respectively, confirming that TGFβ can bind to 104 both ALK1 and ALK5 in HSVSMC, activating separate Smad-mediated signaling pathways. 105
TGFβ1 regulates distinct subsets of pro-migratory or contractile genes by signaling via ALK1 and ALK5 106
Having shown that stimulation of HSVSMC with TGFβ induces the rapid activation of both ALK1 and ALK5 107 pathways, we next aimed to evaluate the effect of ALK1 and ALK5 signaling at the transcriptional level, by 108 performing microarray analysis of HSVSMC stimulated with TGFβ in the presence or absence of 109 pharmacological ALK1 or ALK5 inhibitors (KO2288/KO or SB525334/SB respectively, n=3 patients, venn 110 diagram of 5% FDR [false discovery rate] significant probesets shown in Supplemental Fig.2 ). Interestingly, 111
Ingenuity Pathway Analysis (IPA) of Limma (linear models for microarray data) significant probes (p<0.05) 112
showed that there was little overlap in the molecular and cellular functions and top canonical pathways 113 regulated by TGFβ signaling via ALK5 or ALK1 ( Fig.2A and 2C respectively). Top downregulated genes 114 following ALK5 inhibition included many key mediators of fibrosis, including connective tissue growth factor 115 (CTGF) and fibroblast growth factor-2(FGF2) (Supplemental Fig.3A and B; 116 FGF2 and other top ALK5 targets shown in Fig.2B ), in line with previous studies indicating that ALK5 is 117 responsible for driving the pro-fibrotic actions of TGFβ [13] . Importantly, several genes associated with the 118 contractile SMC phenotype were also highlighted in our array analyses, and qRT-PCR validation in HSVSMC 119 from a further three CABG patients confirmed the ALK5-specific regulation of alpha-smooth muscle actin 120 (ACTA2), calponin (CNN1), transgelin (TAGLN) and smooth muscle myosin heavy chain 11 (MYH11) ( Figure  121 2E). S20 myosin light chain subunit phosphorylation (pS20-MLC), a key regulatory event driving SMC 122 contraction, was also reduced following ALK5 inhibitor treatment in TGFβ-stimulated HSVSMCs (Fig.2F ). 123
To corroborate these findings, we employed an established contractile SMC differentiation protocol [14] . 124
Western immunoblot analysis confirmed a substantial induction of ACTA2, CNN1 and transgelin (SM22α) 125 (Supplemental Fig.4A ), pS20-MLC and total MLC (tMLC; Supplemental Fig.4B ) in HSVSMC cultured in 126 smooth muscle differentiation medium (SMDS) compared to 15% FCS SMC growth medium, peaking at the 127 6 day timepoint. Pharmacological inhibition of ALK5, but not ALK1, significantly downregulated the mRNA 128 expression of ACTA2 and CNN1 in SMDS-treated cells at day 6 (p<0.01, Supplemental Fig.4C and D), further 129 confirming the importance of the ALK5 receptor pathway in the regulation of SMC contractility. 130
Top genes identified in our microarray analysis as dysregulated following ALK1 inhibition were also 131 confirmed by qRT-PCR validation (Fig.2D, p<0 .05 [FADS1, H1F0, PPP1R18 and SCARA3]) and included 132 regulators of cholesterol transport and biosynthesis (Supplemental Fig.3 ; tables C and D). Intriguingly, 133 cholesterol biosynthesis and lipid metabolism were highlighted as two functional pathways regulated by 134
TGFβ via ALK1, suggesting that ALK1 in SMC may play a similar role in promoting lipid uptake as recently 135 observed in ECs [15] . Importantly, IPA analysis highlighted 'cellular movement' as the top cellular function 136 targeted at the transcriptional level following ALK1 inhibition (Fig.2C, top table) . In agreement with this 137 observation, pharmacological inhibition of ALK1 in wound healing assays significantly attenuated TGFβ-138 mediated HSVSMC migration ( Fig.2F , KO2288/KO group; p<0.01, n=7 patients) whereas inhibition of ALK5 139 led to a slight increase in migration ( Fig.2F , SB525334/SB group; p=0.11). Taken together, these data indicate 140 that TGFβ activates two divergent receptor signaling pathways in HSVSMC, inducing migration by activating 141 a specific sub-set of target genes downstream of ALK1 whilst promoting SMC fibrosis and contractility by 142 signaling via ALK5. 143
scRNA-seq analysis identifies nonoverlapping ALK5-and ALK1-dominant HSVSMC subgroups 144
Having identified divergent receptor pathways in HSVSMCs using bulk cell approaches including western 145 blotting, microarray and qPCR analysis, we next aimed to evaluate the heterogeneity of HSVSMC 146 transcriptional responses to TGFβ stimulation using scRNA-seq. Quiesced HSVSMC were stimulated with 147 TGFβ1 for 24 hours prior to harvesting for scRNA-seq using the droplet-based 10x Chromium platform. ). Between these sub-groups, SERPINE1 was most highly expressed in 158 subgroup 4; conversely, this subgroup showed the lowest expression of PLAUR (Fig.3C ). Instead, PLAUR 159 showed high expression in subgroup 0, which was amongst the lowest-expressing subgroups for SERPINE1 160 expression and located at the opposite end of the UMAP Louvain plot (Fig.3C , upper and lower panels). A 161 similar pattern of expression was also observed for CTGF and ID3 (Fig. 3C , upper and lower panels). To 162 determine whether these subgroups represented more ALK5-or ALK1-responsive cell populations, we 163 evaluated the expression of ALK5-and ALK1 signature gene sets, chosen based on their strong dysregulation 164 in our microarray analysis of HSVSMC and including well-established ALK5 & ALK1 target genes 165 (signature gene sets listed in Supplemental Information, Table 4 ). UMAP visualization showed an opposing 166 expression pattern for the two transcriptional signatures ( Having observed differences in the directionality of RNA velocity vectors between opposite poles of the 182 UMAP plot for TGFβ-treated cells (Fig.4B) , we next aimed to analyze how consistent the directionality of 183 velocity vectors was, not only in the two-dimensional embedding visualized with UMAP plots, but also in the 184 original velocity space. To this end, we devised a simple method based on linear algebra, whereby we 185 decompose the velocity vector for each cell into two components: the directional velocity component 186 (measured as flowing away from the cluster centre) and the neutral velocity component (measured as the 187 velocity component minus directional velocity component). We observed that TGFβ-treated HSVSMC 188 displayed lower neutral velocity than control, untreated HSVSMC, suggestive of higher directional velocity 189 and, by extension, increased differentiation ( Fig.4C ). 190
Genetic ablation or pharmacological inhibition of pSmad1/5 attenuates neointima formation in vivo 191
Previous studies in animal models of vascular injury have convincingly shown that TGFβ signaling promotes endothelial to mesenchymal transition [16] , myofibroblast conversion [17] and 193 extracellular matrix deposition [18] . However, no studies to date have addressed the role of ALK1 signaling 194 during neointima formation. First, to identify whether ALK1-mediated TGFβ signaling in SMC might 195 contribute to neointima formation in vivo, we used immunostaining to evaluate the localization of TGFβ 196 signaling pathway components within SMC in an inter-positional cuff mouse model of vein graft disease [19]. 197 Confocal microscopy revealed that TGFβ1, ALK5 and ALK1 were expressed in αSMA+ intimal SMCs 28 198 days following murine vein graft implantation (Fig.5A ). Interestingly, although nuclear localization of both 199 pSmad2/3 and pSmad1/5 was observed in αSMA+ intimal SMCs in remodelled vein graft tissue at the 28-day 200 timepoint, only pSmad2/3 nuclear localization was present in native, un-grafted vena cava (Fig.5B ). Vein 201 graft neointima formation is initiated by the acute, reperfusion injury-mediated activation of the graft 202 endothelium, which is followed by a period of SMC and extracellular matrix expansion [5] . As the 203 contribution of different cell types to neointima formation varies widely depending on the experimental model 204 used [20] and no single model can fully recapitulate human vein graft disease, we chose to also evaluate two 205 models of arterial injury. Similar to our findings in murine vein grafts, we observed TGFβ1, ALK5 and ALK1 206 in αSMA+ intimal SMCs in wire-injured or ligated mouse carotid arteries (Supplemental Fig.8A and 8C) with 207 nuclear localization of pSmad1/5 within SMC only evident in injured vessels (Supplemental Fig.8B and 8D) . 208
These data confirm the expression of ALK1 in intimal SMC and indicate that Smad1/5 is consistently 209 activated in SMC during neointima formation in vivo. 210
We next aimed to assess the contribution of pSmad1/5 signaling in SMCs to neointima formation by 211 inducing acute vascular injury in male c57bl6/J mice treated with 10mg kg-1 LDN193189, which inhibits 212 Smad1/5 phosphorylation downstream of ALK1/ALK2(IC50 ALK1 = 0.8nM, IC50 ALK2 = 0.8nM; [21, 22] ) 213
and Smad1 +/mice or wild-type littermate controls. A substantial neointima was observed in injured carotid 214 arteries from saline-treated c57bl6/J mice and Smad1 +/+ mice ( Fig.3D & 3F ; 2.02±0.5x10 4 and 1.8±0.2x10 4 215 µm 2 , respectively, Supplemental Fig.9A & 9B) . However, neointima formation was substantially reduced in 216 LDN193189-treated mice compared to saline-treated controls (mean intima:media ratio/IMR = 0.26±0.01 vs 217 0.96±0.18, Fig.5C; p<0 .001) and in Smad1 +/mice compared to wild-type siblings (mean IMR = 0.87±0.07 vs 218 1.1±0.05, Fig.5E; p<0 .05), indicating that activation of Smad1/5 following acute vascular injury promotes 219 intimal hyperplasia. 220
ALK1 and associated TGFβ signaling components are widely expressed in hyperplastic pre-implantation 221 saphenous vein grafts 222
Having identified a pathological, pro-migratory role for ALK1/Smad1/5 through our in vitro and in 223 vivo studies, we next sought to evaluate the expression of ALK1 and other components of the TGFβ signaling 224 pathway in intact pre-implantation saphenous vein (SV) segments from CABG patients. Surprisingly, 225 morphometric analyses revealed the presence of pre-existing intimal thickening (defined as an IMR >0.15) in 226 over 88% of SV segments analyzed ( Fig.6A & 6B; n=75, IMR range 0.067-1.37). The pathogenesis of vein 227 graft IH is associated with the acquisition of a proliferative, synthetic phenotype by medial SMC, 228 characterised by the downregulation of mature, contractile SMC proteins such as CNN1 and SMMHC [23] . 229 Accordingly, confocal microscopy of immunostained SV sections with elevated IMR (>0.6) showed 230 decreased CNN and SMMHC ( Fig.6C ; data not shown for SMMHC) but increased PCNA (proliferating cell 231 nuclear antigen; Fig.8D ) in the SV neointima compared to the media (n=8-10). qRT-PCR evaluation of laser-232 capture micro-dissected segments of SV neointima and media provided quantitative confirmation that genes 233 associated with SMC contractility were downregulated in intimal segments, while genes associated with cell 234 cycle progression were concordantly upregulated (Supplemental Fig.10B, n=8 ). Together, these confirm the 235 presence of IH in pre-implantation SV segments from our cohort of CABG patients. 236
Finally, to identify whether ALK1 signaling in SMC might contribute to vein graft IH we evaluated 237 the localization of TGFβ signaling pathway components within SV samples showing substantial pre-existing 238 neointima formation (IMR>0.6; n=7-15). Immunostaining revealed that TGFβ1, TβR2, ALK5 and ALK1 239 were all highly expressed in αSMA+ intimal SMCs (Fig.6E) , while dual staining for TβR2 and ALK5 or 240 ALK1 showed strong colocalization between ALK1/ALK5 and TβR2 (Fig.6F ). Both pSmad2/3 and pSmad1/5 241 were localized to the nuclei of intimal SMCs, which also showed elevated expression of the transcriptional 242 targets CTGF and ID1 (Fig.6E ). Furthermore, gene expression analysis of laser-capture microdissected SV 243 segments confirmed the expression of the top transcriptional targets identified in our HSVSMC microarray 244 analyses (CTGF, FGF2, SCARA3 and FADS1; Supplemental Fig.11 ). Interestingly, we also observed 245 abundant nuclear-localized pSmad2/3 and pSmad1/5 in αSMA+ intimal SMCs in three failed SVG specimens 246 obtained from patients undergoing cardiac transplantation (Supplemental Fig.12A & 12B) . Together, these 247 data indicate that ALK1 expression in SMC within pre-implantation SV tissue from CABG patients may be 248 clinically relevant to the pathogenesis of vein graft neointima formation and, ultimately, failure. 249
Discussion
250
Although previous studies have extensively characterized the pro-fibrotic role of ALK5 in animal 251 models of vascular injury [16] [17] [18] , no studies to date have addressed the role of ALK1 signaling during 252 neointima formation following CABG surgery. We report for the first time that ALK1 and its co-receptor 253 endoglin, which can potentiate ALK1 signaling, are highly expressed in primary human vein graft SMCs from 254 CABG patients (HSVSMC); we also show that TGFβ can bind both these receptors at the cell surface. 255 Importantly, using ALK inhibitors and siRNA approaches we demonstrate that induction of Smad1/5 256 phosphorylation by TGFβ in HSVSMC is mediated by ALK1, with canonical Smad2/3 phosphorylation 257 occurring downstream of ALK5. The ability of TGFβ to signal via two different type I receptors was first 258 identified in ECs, with early studies showing that activation of ALK1/pSmad1/5 by TGFβ induced EC 259 proliferation and migration whereas activation of ALK5/pSmad2/3 antagonized these processes [28] . While 260 our results contrast with previous studies in cultured human aortic SMCs, where phosphorylation of Smad1/5 261 was shown to be primarily mediated by ALK5 [29] , another group has recently demonstrated that TGFβ-262 induced Smad1/5 phosphorylation in new-born murine pulmonary artery SMCs involves ALK1 [30] , 263 suggesting that the ability of TGFβ to activate this signaling mechanism varies between SMC sub-types. This 264 context-specificity is an established hallmark of TGFβ superfamily signaling and critically influences cellular 265 responses to TGFβ; moreover, studies show that type I receptors bind different ligands in different contexts, 266 with ALK1 able to act downstream of bone morphogenetic protein-9 (BMP9) and BMP10 as well as TGFβ 267 [31, 32] . Interestingly, Daly et al [33] reported that heterotetrameric receptor complexes incorporating ALK5 268 and ALK1 generate mixed pSmad complexes which have lower affinity for BMP response elements in 269 canonical Smad1/5 target genes such as ID1 and ID3. This has raised questions around the functional 270 relevance of ALK1:TGFβ signaling. Whilst we cannot exclude the generation of mixed Smad complexes in 271 our experiments, the nuclear localization of pSmad1/5 and sustained induction of ID1 expression (and ID3; 272 data not shown) following TGFβ stimulation clearly indicates that activation of ALK1 is functionally 273 significant in HSVSMC. 274
Our qRT-PCR validated, whole genome expression profiling of HSVSMC provides further evidence that 275 ALK1 and ALK5 are both key mediators of TGFβ signaling in vein graft SMCs, showing that TGFβ regulates 276 distinct transcriptional pathways by signaling via these two receptors. Specifically, we observed that the 277 upregulation of SMC contractility genes by TGFβ was driven by ALK5, associated with enhanced pS20-MLC 278 expression and corroborated using an established SMC contractile differentiation model. Interestingly, our 279 scRNA-seq analyses suggested that treated cells were differentiating along separate lineages, with the ALK5-280 dominant and ALK1-dominant subgroup separated in the UMAP embedding space. Computational estimation 281 of the directionality of RNA velocity vectors indicated reduced neutral velocity in TGFβ-treated HSVSMC 282 compared to control, untreated HSVSMC, indicative of increased differentiation following TGFβ treatment. 283
We would like to note however, that estimation of RNA velocity vectors is still an active area of research and 284 our method of RNA vector decomposition would have to be tried on larger sample sizes before it can lead to 285 any definitive biological conclusions. 286
Previous studies performed in SMCs of arterial origin have shown that activated Smad2/3 complexes 287 interact with Smad binding elements in the αSMA (ACTA2?), SM22α (TAGLN) and SMMHC (MYH11) 288 promoters [34] . Our findings therefore show that this transcriptional mechanism is highly conserved across 289 venous and arterial beds, highlighting a fundamental role for ALK5 in the regulation of SMC contractility. 290
We also found similarities between our ALK5 target gene dataset and those identified from previous 291 microarray analyses performed in ECs, in which CTGF and collagen genes were shown to be specific targets 292 of the ALK5 pathway. This suggests wider conservation of TGFβ:ALK5 gene targets across cell types [35, 293 36] . Conversely, the ALK1-specific transcriptional targets we identified showed little overlap with known 294 TGFβ or ALK1 target genes [36, 37] , and included genes such as SCARA3, which encodes a scavenger 295 receptor that promotes the uptake of modified lipoproteins and plays an important role in fatty streak 296 development during atherogenesis [38] . This may be linked to differences in experimental approach: previous 297 studies overexpressed a constitutively active form of ALK1 in ECs, whilst we employed a recently-developed 298 pharmacological ALK1 inhibitor (K02288) to pinpoint TGFβ-specific targets downstream of ALK1 in CABG 299 patient SMC. Alternatively, this may indicate that the response to ALK1 activation by TGFβ is more 300 sensitive to cell context, varying according to the presence or absence of transcriptional coregulators. 301
Interestingly, the pro-migratory transcription factors Sox4 and Runx1 (Runt-related transcription factor 1) 302 ([39] [40]), which can act as DNA binding co-factors for Smad1/Smad5, are upregulated by TGFβ in 303 HSVSMCs (2.1-and 3-fold, respectively; data not shown); by integrating TGFβ:ALK1 signaling, co-304 regulators such as Sox4 and Runx1 may help promote HSVSMC migration. In support of this hypothesis, our 305 microarray analyses and wound healing assays identified a novel role for ALK1 in the regulation of HSVSMC 306 migration. SMC migration is integral to vein graft neointima formation, during which proliferative medial 307 SMCs move into the expanding intima. ALK1 expression and activation in HSVSMCs may therefore be a 308 pathophysiological response to injury, promoting SMC migration and negative, inward vein graft remodeling. 309
In agreement with previous reports [10, 18] we found that TGFβ, ALK5 and ALK1 are expressed by 310 neointimal SMCs in injured mouse carotid arteries and remodeled vein grafts. We also observed that 311 pSmad2/3 and pSmad1/5 were localized to the nuclei of SMCs in mouse vein grafts, in correlation with the 312
Cooley et al study on EndMT in VGF [41] . Interestingly, while ALK5 signaling was active in both non-313 injured and injured vessels, ALK1 signaling was only activated following vascular injury, evidenced by the 314 absence of nuclear pSmad1/5 in uninjured vessels. Whilst BMPs can also activate Smad1/5 via ALK2, 3 and 315 6, previous studies indicate that only ALK1 expression is upregulated in wire-injured arteries 28 days 316 following injury [10] . Together with the substantially reduced neointima formation we observed in mice 317 treated with the ALK1/2 inhibitor LDN193189 and in heterozygous null Smad1 mice, these data indicate that 318 activation of the ALK1/Smad1/5 pathway is involved in the acute phase response to vascular injury. The 319 identity of the ligand(s) triggering Smad1/5 activation in vivo remains to be elucidated; although our in vitro 320 work clearly demonstrates that TGFβ is an active ligand for ALK1 in HSVSMC, ALK1 also binds BMP9 and 321 BMP10 with high affinity [42] . The role of alternate ALK1 ligands during neointima formation following 322 acute vascular injury therefore requires further investigation. However, we were unable to detect BMPRII 323 expression in injured mouse arteries following carotid ligation (data not shown), which suggests a role for 324 TGFβ:ALK1 in the phosphorylation of Smad1/5 in SMCs during neointima formation after vascular injury. 325
To evaluate the clinical relevance of ALK1 expression in cultured HSVSMC, we performed detailed 326 histological assessments of surplus pre-implantation SVG tissues from a cohort of 75 patients undergoing 327 CABG surgery, reasoning that the presence of ALK1 in SMC within these samples may provide further 328 evidence supporting a role for this pathway in vein graft neointima formation. We were surprised to observe 329 that the vast majority of these vessels showed significant pre-existing IH, with IMRs measuring >0.15 in 88% 330 of the vein graft segments analyzed. Interestingly, several studies including ex vivo organ culture experiments 331
[43] and ultrasonographic studies of CABG grafts in situ [44, 45] indicate that pre-existing intimal thickening 332 within SVG can act as a substrate for accelerated neointima formation following vein graft implantation and 333 increase the risk of failure. Follow-up studies of our cohort of CABG patients will be of value in determining 334 the clinical impact of our histological observations. Of note, ALK1 was highly expressed in αSMA+ intimal 335 SMCs from the most hyperplastic vein graft segments (IMR>0.6), associated with reduced mature SMC 336 marker expression and increased markers of proliferation. Although we cannot exclude the contribution of 337 alternate ALK1 ligands, clinical studies of re-stenotic arteries clearly show, that TGFβ is acutely and 338 chronically upregulated at vascular injury sites [reviewed in Bradshaw et al, 2018] . Together with our data 339
showing localization of ALK1, TβRII, pSmads and target genes to vein graft SMCs, this is strongly 340 suggestive of a role for TGFβ:ALK1 in the development of vein graft IH. 341
In summary, the present study shows that TGFβ activates two distinct Smad-mediated signaling 342 pathways downstream of ALK5 and ALK1 in vein graft SMC from CABG patients, inducing receptor-343 specific transcriptional networks associated with SMC contractility and migration, respectively. Smad1/5 344 activation is identified as a pathological hallmark of the SMC response to acute vascular injury, promoting 345 neointima formation and inward remodeling. e. f. g.
Figure 3. scRNA-seq analysis identifies nonoverlapping ALK5-and ALK1-dominant HSVSMC subgroups
Quiesced HSVSMC were stimulated with TGFβ for 24h prior to harvesting for scRNA-seq using the droplet-based 10x Genomics system, at an average read depth of~50,000/cell. 5,245 untreated cells and 7,073 TGFβ-treated cells from the same patient were analysed using a Python pipeline (A) Cells were separated into two batches for analysis (TGFβ-treated/orange and untreated control/blue), with expression of SERPINE1, CTGF, ID3 and PLAUR mapped (L-R with TGFβ for 24h prior to harvesting for scRNA-seq using the droplet-based 10x Genomics system, at an average read depth of~50,000/cell. RNA velocity analyses were performed on 5,245 untreated cells (A) and 7,073 TGFβ-treated cells (B) from the same patient. Arrows indicate directionality in the vector space, underlying colours correspond to Louvain grouping. Linear algebra was used to decompose velocity vectors for each cell into two components, a neutral velocity component and a directional component. Neutral directional components of treated and untreated cells were plotted against the relative magnitude of neutral velocity; increased neutral velocity corresponds to reduced directional movement in the RNA velocity analysis (C) c.
d.
Figure 5. Smad1/5 activation promotes neointima formation following acute vascular injury in mice (A)
Immunostaining for TGFβ1, ALK1 or ALK5 in in remodelled mouse vein graft sections. (B) Dual immunostaining for pSmad2/3 and pSmad1/5 in pre-implantation (day 0, upper panels) and remodelled (day 28, lower panels) mouse vein grafts; SMC are identified using the SMC marker αSMA. Confocal images of immunostained sections are representative images from n=3 animals. Dotted line indicates location of the lumen. (C, D) Morphometric assessment of intima:media area ratio in LDN193189-treated (10mg/kg IP every 48h) or saline-treated control mice following acute vascular injury (n=5/6 per group). (E/F) morphometric assessment of intima:media area ratio following acute vascular injury in male Smad1 +/mice or littermate controls (Smad +/+ ; n=8/group) *=p<0.05, ***=p<0.001 compared to wild-type/control by students T-test; IMR data represent mean ± SEM. 
